Cipher acquires three dermatology products from Astion Pharma – Healio
Cipher acquires three dermatology products from Astion PharmaHealioThe products include Dermadexin, a topical barrier-repair cream containing the pharmacologically active ingredient P3GCM. Dermadexin was approved in the European Union (EU) in 2014 as a Class III medical device for treating seborrheic dermatitis.
Cipher acquires worldwide rights to three products from Astion
Cipher Pharmaceuticals Inc. Today announced it has strengthened its product pipeline by acquiring the worldwide rights to three products from Astion Pharma, a Denmark-based specialty pharmaceutical company.